A detailed history of Stuart Chaussee & Associates, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Stuart Chaussee & Associates, Inc. holds 16 shares of AMGN stock, worth $4,480. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16
Previous 16 -0.0%
Holding current value
$4,480
Previous $4,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 14, 2020

SELL
$182.24 - $241.7 $21,868 - $29,004
-120 Reduced 88.24%
16 $3,000
Q2 2019

Aug 08, 2019

SELL
$166.7 - $195.41 $21,671 - $25,403
-130 Reduced 48.87%
136 $25,000
Q1 2019

May 08, 2019

BUY
$180.87 - $203.88 $45,217 - $50,970
250 Added 1562.5%
266 $51,000
Q4 2017

Feb 05, 2018

BUY
$168.79 - $188.59 $2,700 - $3,017
16 New
16 $3,000
Q4 2017

Feb 02, 2018

SELL
$168.79 - $188.59 $2,700 - $3,017
-16 Closed
0 $0
Q3 2017

Oct 31, 2017

BUY
$167.29 - $191.0 $2,676 - $3,056
16
16 $189,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $150B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Stuart Chaussee & Associates, Inc. Portfolio

Follow Stuart Chaussee & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stuart Chaussee & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stuart Chaussee & Associates, Inc. with notifications on news.